Alimera Sciences Inc

Alimera Sciences — Q4 2018 Earnings Presentation

13 slides from Alimera Sciences's earnings presentation, Feb 19, 2019

  1. Slide 1: Fourth Quarter & 2018 Results

    Exhibit 99.2 Fourth Quarter & 2018 Results February 19, 2019 | Nasdaq: ALIM

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation and the conference call and webcast it accompanies include or will include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s belief, expectation, or anticipat

  3. Slide 3: New Leadership Team

    New Leadership Team Strong team with significant industry experience Rick Eiswirth Phil Jones Dave Holland Phillip Ashman CEO & President CFO Chief Marketing Officer & Chief Operating Officer, SVP Corporate Communications Managing Director Europe 3

  4. Slide 4: Fourth Quarter & 2018 Overview

    +31% $47.0M Fourth Quarter & Growth 2018 Overview $35.9M • 2018 Net Revenue of $47.0 million, 31% annual growth +66% Growth $15.1M • 4Q18 Net Revenue of $9.1M $15.1 million, 66% growth vs 4Q17 4Q17 4Q18 2017 2018 Revenue 4

  5. Slide 5: U.S. End User Demand

    U.S. End User Demand 1200 1019 977 1000 955 896 851 850 837 827 788 800 777 705 600 533 536 502 467 400 200 167 0 First Quarter Second Quarter Third Quarter Fourth Quarter 2015 2016 2017 2018 5

  6. Slide 6: International Growth Segment

    +49% $14.6M International Growth Segment • 138% 4Q18 international $9.8M revenue growth $6.2M +138% • 2018 International Growth revenue of $14.6 million, up 49% vs. 2017 $2.6M 4Q17 4Q18 2017 2018 International Revenue 6

  7. Slide 7: Income Statement

    Income Statement Three Months Ended Three Months Ended Twelve Months Ended Twelve Months Ended ($000’s) December 31, 2018 December 31, 2017 December 31, 2018 December 31, 2017 Revenue $ 15,114 $ 9,142 $ 46,970 $ 35,912 Operating 13,717 13,837 51,961 48,926 Expenses Net Loss (1,249) (7,224) (16,383)

  8. Slide 8: U.S. End User Demand

    U.S. End User Demand • Historical 1200 inconsistency between distributor orders 1000 and end user demand • End user demand 800 represents units purchased by physicians and pharmacies from 600 Alimera’s distributors 400 200 0 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18

  9. Slide 9: Income Statement

    Income Statement Three Months Ended Three Months Ended Twelve Months Ended Twelve Months Ended ($000’s) December 31, 2018 December 31, 2017 December 31, 2018 December 31, 2017 Revenue $ 15,114 $ 9,142 $ 46,970 $ 35,912 Operating 13,717 13,837 51,961 48,926 Expenses Net Loss (1,249) (7,224) (16,383)

  10. Slide 10: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA Three Months Ended Three Months Ended Twelve Months Ended Twelve Months Ended ($000’s) December 31, 2018 December 31, 2017 December 31, 2018 December 31, 2017 GAAP Net Loss $ (1,249) $ (7,224) $ (16,383) $ (22,001) Adjustments to net loss:

  11. Slide 11: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA Alimera believes that the non-GAAP financial information provided in this presentation can assist investors in the overall understanding of its financial performance when considered together with GAAP figures. This presentation contains a d

  12. Slide 12: Growth Drivers

    Greater Penetration Organic 3 Year Retreatments Growth Uveitis Indication Drivers Geographic Expansion 12

  13. Slide 13: Fourth Quarter & 2018 Results

    Fourth Quarter & 2018 Results February 19, 2019 | Nasdaq: ALIM

Alimera Sciences — Q4 2018 Earnings Presentation on 6ix